Mineralys Therapeutics, Inc.

We had a fantastic time at the #HeartWalk in Philadelphia! Mineralys is proud to support the American Heart Association and its mission to improve heart health. #iHeartScience #PhiladelphiaHeartWalk

We have completed enrollment for our second pivotal trial evaluating lorundrostat in uncontrolled and resistant #hypertension, Launch-HTN, with topline data now anticipated in mid first half of 2025. Read our press release to learn more: https://lnkd.in/e5xxgefc #MLYS #CVD #HighBloodPressure

Reminder to join us this Wednesday at 10:00am ET for a virtual discussion on the unmet medical need in uncontrolled and resistant hypertension and lorundrostat as a potential treatment.   Register here: https://lnkd.in/dtqFfvqf #HighBloodPressure #CVD #Healthcare #Innovation

If you’re at BioFuture in NYC, join our Chief Business Officer, Minji Kim, on the 12th floor tomorrow at 2:00pm ET for a panel discussion around the upcoming innovations and continued unmet needs in cardiovascular disease in the age of #obesity drugs.    #BioFuture #CardiovascularDisease #CVD #Healthcare #Innovation

Join us at 10:00am ET on Wednesday, October 30, for a virtual KOL event on the unmet medical need in uncontrolled and resistant #hypertension and the potential of lorundrostat, our novel, highly selective aldosterone synthase inhibitor, to change the current treatment paradigm. Speakers include Luke Laffin, MD (Cleveland Clinic), Matt Luther, MD, MSCI (Vanderbilt University Medical Center), and Rhian Touyz, MBBCh, PhD, FRCP, FRSE, FCAHS, FMedSci (McGill University Health Centre). Full details: https://lnkd.in/dmnw738d $MLYS #CVD #HighBloodPressure

We have achieved the enrollment target of 261 subjects in the pivotal Advance-HTN trial evaluating lorundrostat for the treatment of uncontrolled or resistant #hypertension, putting us on track to announce topline data in Q1 2025. Read our press release to learn more: https://lnkd.in/eG7sbBwR $MLYS #CVD #HighBloodPressure

Today we reported financial results for the quarter ending June 30, 2024. Read our press release for highlights, including anticipated readouts from our pivotal trials for lorundrostat in #hypertension, and proof-of-concept in hypertension and #ckd. Read our press release to learn more: https://lnkd.in/edYEWh7r $MLYS

At Mineralys Therapeutics, our purpose is to create more, better days for people dealing with #hypertension and cardio-renal-metabolic disorders. This week, our team came together in Boulder, Colorado, for our annual all-staff meeting. United by this purpose, we delved into the opportunity we have to transform the treatment of hypertension and for a multitude of cardio-renal-metabolic disorders. The summit wasn't just about business. We also dedicated time to giving back to the Boulder community with a volunteer initiative and a refreshing group hike. It was a powerful reminder of the impact our work can have on people. As we move forward, the energy and ideas generated during our time together will propel us through the rest of 2024 and beyond. We are a team united in our commitment to addressing some of the largest unmet medical needs today. Together, we're working tirelessly to create more, better days. #Aldosterone #CardioRenalMetabolic #DrugDiscovery #Leadership #TeamWork #PatientCare

Last week we announced the appointment of Alexander M. Gold, MD, to our Board of Directors. Dr. Gold brings over 20 years of experience leading the development, approval, and commercialization of new therapies. $MLYS

There is a link between uncontrolled #hypertension and certain conditions like obesity, where dysregulated aldosterone may be hindering blood pressure control. In these patients, a better-targeted treatment may be the solution. #HighBloodPressureMonth